Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics Inc ABEO
$6.42
▼ -0.77%
($-0.05)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$6.51
Prev Close
$6.47
Day Range
$6.23 – $6.58
52W Range
$4.00 – $7.54
Market Cap
$365.91M
P/E (TTM)
5.53
Beta
1.33
EPS (TTM)
$0.87
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1980-09-19 |
| Shares Out. | 57,000,000 |
| Website | abeonatherapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 226 |
| Revenue | $8.7M |
| Gross Profit | $6.0M |
| Net Income | -$17.1M |
| Free Cash Flow | -$85.2M |
| Total Assets | $198.5M |
| Total Liabilities | $53.6M |
| Equity | $144.9M |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Abeona Therapeutics Inc is a publicly traded company under the ticker symbol ABEO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)